NCT03953742View on ClinicalTrials.gov

Study of CPI-200 in Patients With Advanced Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

February 1, 2022

Study Completion Date

February 15, 2022

Conditions
Advanced Solid Tumor
Interventions
DRUG

CPI-200

CPI-200 will be administered via intravenous infusion on Day 1 of a 21-Day cycle

Trial Locations (1)

49546

South Texas Accelerated Research Therapeutics (START Midwest), Grand Rapids

Sponsors
All Listed Sponsors
lead

Coordination Pharmaceuticals, Inc.

INDUSTRY